Drug Approval | April 07, 2022
Lupin launches Merzee capsules in the United States
Merzee is a generic equivalent of Taytulla of Allergan Pharmaceuticals International
Merzee is a generic equivalent of Taytulla of Allergan Pharmaceuticals International
Sevelamer Hydrochloride tablets, 800 mg is a generic equivalent of Renagel tablets, 800 mg
Oxcarbazepine ER Tablets (RLD Oxtellar XR) had estimated annual sales of US$ 206 million in the US (IQVIA MAT April 2025)
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Rifaximin tablets had annual sales of US$ 2672.9 mn in the United States (IQVIA MAT March 2025)
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
First pivotal Phase 3 trial to show superiority of Keytruda plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC
Manageable safety profile and encouraging antitumor activity observed for MK-1084 in KANDLELIT-001, both as a monotherapy and in studied combinations
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Subscribe To Our Newsletter & Stay Updated
